Rofecoxib: An update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects

Journal of Pharmacy and Pharmacology

Volumn 55, Issue 7, 2003, Pages 859-894

  Ahuja, Naveen ^a   Singh, Amarjit ^b   Singh, Bhupinder ^a  

^a PANJAB UNIVERSITY   (India)

^b Panacea Biotec Ltd   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTACID AGENT; ARTHROTEC; CARBAMAZEPINE; CELECOXIB; CIMETIDINE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; DIURETIC AGENT; DRUG METABOLITE; ERYTHROMYCIN; IBUPROFEN; INDOMETACIN; KETOCONAZOLE; KETOPROFEN; MELOXICAM; MIDAZOLAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXIDOREDUCTASE; PARACETAMOL; PHENOBARBITAL; PHENYTOIN; PREDNISOLONE; PREDNISONE; RIFAMPICIN; ROFECOXIB; TRAMADOL; UNINDEXED DRUG;

ABDOMINAL PAIN; ACUTE PANCREATITIS; ALZHEIMER DISEASE; ANALGESIC ACTIVITY; ANEMIA; ANGINA PECTORIS; ANGIONEUROTIC EDEMA; ANTIINFLAMMATORY ACTIVITY; ANTIPYRETIC ACTIVITY; ASEPTIC MENINGITIS; BACKACHE; BIOEQUIVALENCE; BODY FLUID; CARCINOGENICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTATIC HEPATITIS; CLINICAL TRIAL; COLITIS; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DIARRHEA; DIGESTIVE SYSTEM INJURY; DIGESTIVE SYSTEM ULCER; DISEASE EXACERBATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG DISPOSITION; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FATALITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INFORMATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG STABILITY; DRUG TOLERABILITY; DRUG TOXICITY; DRUG USE; DUCTUS ARTERIOSUS OBLITERATION; DYSMENORRHEA; DYSPEPSIA; EDEMA; ELECTROLYTE BLOOD LEVEL; ELECTROLYTE DISTURBANCE; ENZYME INHIBITION; ENZYME SPECIFICITY; EPIGASTRIC DISCOMFORT; ERYTHEMA MULTIFORME; EXPERIMENTAL MODEL; FETUS WASTAGE; FOOD DRUG INTERACTION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HEARTBURN; HEMATEMESIS; HEMATOLOGIC DISEASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOALDOSTERONISM; INTESTINE INJURY; INTESTINE NECROSIS; INTRACARDIAC THROMBOSIS; KIDNEY FAILURE; KIDNEY VEIN THROMBOSIS; LIVER FAILURE; LIVER METABOLISM; LOW DRUG DOSE; LUNG EDEMA; MALIGNANT NEOPLASTIC DISEASE; MELENA; MUTAGENICITY; NATRIURESIS; NAUSEA; NEPHROTOXICITY; NONHUMAN; OSTEOPOROSIS; PAIN; PARESTHESIA; PEPTIC ULCER BLEEDING; PERIPHERAL EDEMA; PHARMACODYNAMICS; PHOTOSENSITIVITY; PHYSICAL CHEMISTRY; PHYSIOLOGY; PLASMA PROTEIN BINDING; POLYP; POSTOPERATIVE PAIN; PYLORUS STENOSIS; RENOVASCULAR HYPERTENSION; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SINUSITIS; SKIN DEFECT; SODIUM URINE LEVEL; SOLID STATE; STEADY STATE; STOMACH EROSION; STOMACH PRESSURE; TERATOGENICITY; THROMBOEMBOLISM; THROMBOSIS; TOOTH PAIN; TRANSIENT ISCHEMIC ATTACK; ULCER; ULCER PERFORATION; UPPER GASTROINTESTINAL TRACT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA; VERTEBRA MALFORMATION; VERTIGO; WEIGHT GAIN;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS; CLINICAL TRIALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; ISOENZYMES; LACTONES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SULFONES;

EID: 0041664973     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357021387     Document Type: Review

References (309)

1. Acevedo, E., Castaneda, O., Ugaz, M., Beaulieu, A. D., Pons-Estel, B., Caeiro, F., Casas, N., Garza-Elizondo, M., Irazoque, F., Hinojosa, W., Gutierrez-Urena, S., Vandormael, K., Rodgers, D.B., Laurenzi, M. (2001) Tolerability profiles of rofecoxib (Vioxx) and Arthrotec. A comparison of six weeks treatment in patients with osteoarthritis. Scand. J. Rheumatol. 30: 19-24
2. Adelman, A. (2001) Is rofecoxib safer than naproxen? J. Fam. Pract. 50: 204
3. Afflitto, L. (2000) Selective COX-2 inhibitors and the surgical patient. Plast. Surg. Nurs. 20: 91-93
4. Ahmad, S. R., Kortepeter, C., Brinker, A., Chen, M., Beitz, J. (2002) Renal failure associated with the use of celecoxib and rofecoxib. Drug Saf. 25: 537-544
5. Aisen, P. S. (2002) Evaluation of selective COX-2 inhibitors for the treatment of Alzheimer's disease. J. Pain Symptom Manage. 23 (Suppl. 4): S35-S40
6. Ajithadas, A., Anusuya, P., Balamarriapan, C., Lakshamanan, M. K., Nanjappan, K., Kumar, P.A.R. (2001) Reverse phase high performance liquid chromatographic determination of rofecoxib in tablets. Indian Drugs 38: 523-525
7. Akaraserennont, P., Mitchell, J. A., Appleton, I., Thiemermann, C., Vane, J. R. (1994) Involvement of tyrosine kinase in the induction of cyclooxygenase and nitric oxide synthase by endotoxin in cultured cells. Br. J. Pharmacol. 113: 1522-1528
8. Amaravadi, R. K., Jacobson, B. C., Solomon, D. H., Fischer, M. A. (2002) Acute pancreatitis associated with rofecoxib. Am. J. Gastroenterol. 97: 1077-1078
9. Aravind, M. K., Prescilla, R., Ofenstein, J. P. (2002) A rapid and sensitive high-performance liquid chromatography assay for rofecoxib in human serum. J. Chromatogr. Sci. 40: 26-28
10. Aristo Pharmaceuticals Limited (2000) Introducing Rofib India's First Rofecoxib with the Beta Cyclodextrin Advantage: A Scientific Brief. Aristo Pharmaceuticals Limited, Mumbai, India
11. Atkinson, H. G. (2002) COX-2 inhibitors: Better than traditional NSAIDs? Vioxx and Celebrex may be no less risky than NSAIDs. Health News 8:5
12. Baillie, T. A., Halpin, R. A., Matuszewski, B. K., Geer, L. A., Chavez-Eng, C. M., Dean, D., Braun, M., Doss, G., Jones, A., Marks, T., Mellilo, D., Vyas, K. P. (1991) Mechanistic studies on the reversible metabolism of rofecoxib to 5-hydroxyrofecoxib in the rat: Evidence for transient ring opening of a substituted 2-furanone derivative using stable isotope-labeling techniques. Drug Metab. Dispos. 29: 1614-1628
13. Bannwarth, B., Treves, R., Euller-Ziegler, L., Rolland, D., Ravaud, P., Dougados, M. (2003) Adverse events associated with rofecoxib therapy: Results of a large study in community-derived osteoarthritic patients. Drug Saf. 26 49-54
14. Barden, J., Edwards, J. E., McQuay, H. J., Moore, R. A. (2002) Single-dose rofecoxib for acute postoperative pain in adults: A quantitative systematic review. BMC Anesthesiol 2: 4
15. Bekker, A., Cooper, P. R., Frempong-Boadu, A., Babu, R., Errico, T., Lebovits, A. (2002) Evaluation of preoperative administration of the cyclooxygenase-2 inhibitor rofecoxib for the treatment of postoperative pain after lumbar disc surgery. Neurosurgery 50: 1053-1057
16. Bellamy N. (1995) Outcome measurement in osteoarthritis clinical trials. J. Rheumatol. 22:49-51
17. Bellamy, N., Buchanan, W. W., Goldsmith, C. H., Campbell, J., Stitt, W. L. (1988) Validation study of WOMAC: A health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J. Rheumatol. 15: 1833-1840
18. Berg, J., Christoph, T., Widerna, M., Bodenteich, A. (1997) Isoenzyme specific cyclooxygenase inhibitors: A whole cell assay system using the human erythroleukemic cell line HEL and the human monocytic cell line mono mac 6. J. Pharmacol. Toxicol. Methods 37: 179-186
19. Berges-Gimeno, M. P., Camacho-Garrido, E., Garcia-Rodriguez, R. M., Alfaya, T., Martin Garcia, C., Hinojosa, M. (2001) Rofecoxib safe in NSAID hypersensitivity. Allergy 56: 1017-1018
20. Berti, M., Danelli, G., Albertin, A., Deni, F., Moizo, E., Muzzolon, F. (2001) Systemic analgesia after block peripheral. Minerva Anestesiol. 67 (Suppl. 9): 195-199
21. Bingham, C. O. (2002) Development and clinical application of COX-2-selective inhibitors for the treatment of osteoarthritis and rheumatoid arthritis. Cleve. Clin. J. Med. 69 (Suppl. 1): SI5-SI12
22. Blain, H., Jouzeau, J. Y., Blain, A., Terlain, B., Trechot, P., Touchon, J., Netter, P., Jeandel, C. (2000) Non-steroidal antiinflammatory drugs with selectivity for cyclooxygenase-2 in Alzheimer's disease. Rationale and perspectives. Presse Med. 29: 267-273
23. Block, S.H. (2002) Chronic sinusitis with rofecoxib. J. Allergy Clin. Immunol. 109: 373-374
24. Block, G. A., Lines, C. R. (2002) Combination of a GABAA Alpha 5 Inverse Agonist and COX-2 Inhibitor, NSAID, estrogen or vitamin E. Merck & Co., Inc., Rahway, NJ, US 6440967
25. Bombardier, C. (2002) An evidence-based evaluation of the gastrointestinal safety of coxibs. Am. J. Cardiol. 89: 3D-9D
26. Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., Kvien, T. K., Schnitzer, T. J. (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR study group. N. Engl. J. Med. 343: 1520-1528
27. Bonnel, R. A., Villalba, M. L., Karwoski, C. B., Beitz, J. (2002) Aseptic meningitis associated with rofecoxib. Arch. Intern. Med. 162: 713-715
28. Boolbol, S. K., Dannenberg, A. J., Chadburn, A., Martucci, C., Guo, X. J., Ramonetti, J.T., Abreu-Goris, M., Newmark, H. L., Lipkin, M. L., DeCosse, J. J., Bertagnolli, M. M. (1999) Cyclooxygenase-2 overexpression and tumour formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res. 56: 2556-2560
29. Bottner, F., Roedl, R., Wortler, K., Grethen, C., Winkelmann, W., Lindner, N. (2001) Cyclooxygenase-2 inhibitor for pain management in osteoid osteoma. Clin. Orthop. 393: 258-263
30. Brater, D. C. (1999) Effects of nonsteroidal antiinflammatory drugs on renal function: Focus on cyclooxygenase-2-selective inhibition. Am. J. Med. 107: 65S-70S
31. Brater, D. C. (2002) Renal effects of cyclooxygenase-2-selective inhibitors. J. Pain Symptom Manage. 23 (Suppl. 4): S15-S20
32. Brater, D. C., Harris, C., Redfern, J. S., Gertz, B. J. (2001) Renal effects of COX-2-selective inhibitors. Am. J. Nephrol. 21: 1-15
33. Brain, F. M. (2001) COX-2 inhibitors and cardiovascular risk: Point and counterpoint. Cleve. Clin. J. Med. 68: 957-960
34. Brooks, P. M., Day, R. O. (2000) COX-2 inhibitors. Med. J. Aust. 173: 433-436
35. Brouwers, J. R. B. J., De Smet, P. A. G. M. (1994) Pharmacokinetic-pharmacodynamic drug interaction with nonsteroidal antiinflammatory drugs. Clin. Pharmacokinet. 27: 462-485
36. Brown, C. H. (2000) Effect of rofecoxib on the antihypertensive activity of lisinopril. Ann. Pharmacother. 34: 1486
37. Brown, J., Morrison, B. W., Christensen, S., Dunkley, V., Sandler, M., Turpin, M., Harmsen, B., Yuan, W., Lesneski, L., Seidenberh, B. (1999a) MK-0966 50 mg versus ibuprofen 400 mg in post-surgical dental pain. (abstract) Clin. Pharmacol. Ther. 65: 118, PI-4
38. Brown, J., Morrison, B. W., Bitner, M., Woolsey, C., Sandler, M., Dunkley, V., Kotey, P., Seidenbeerg, B. (1999b) The COX-2 specific inhibitor, MK-0966, is effective in the treatment of primary dysmenorrhoea. (abstract) Clin. Pharmacol. Ther. 65: 118, PI-5
39. Brune, K., Neubert, A. (2001) Pharmacokinetic and pharmacodynamic aspects of the ideal COX-2 inhibitor: A pharmacologist's perspective. Clin. Exp. Rheumatol. 19 (6 Suppl 25): S51-S57
40. Buchan, I. E., Bird, H.A. (1991) Drug interactions in arthritic patients. Ann. Rheum. Dis. 50: 680-681
41. Burleigh, M. E., Babaev, V. R., Oates, J. A., Harris, R. C., Gautam, S., Riendeau, D., Marnett, L. J., Morrow, J. D., Fazio, S., Linton, M. F. (2002) Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation 105: 1816-1823
42. Cannon, G. W., Caldwell, J. R., Holt, P., McLean, B., Seidenberg, B., Bolognese, J., Ehrich, E., Mukhopadhyay, S., Daniels, B. (2000) Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: Results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib phase III protocol 035 study group. Arthritis Rheum. 43: 978-987
43. Carder, K. R., Weston, W. L. (2002) Rofecoxib-induced instant aquagenic wrinkling of the palms. Pediatr. Dermatol. 19:353-355
44. Caroli, A., Monica, F. (2001) Severe upper gastrointestinal bleeding during treatment with rofecoxib for osteoarthritis. Am. J. Gastroenterol. 96: 1663-1665
45. Catella, F., Nowak, J., Fitzgerald, G. A. (1986) Measurement of renal and non-renal eicosanoid synthesis. Am. J. Med. 81: 23-29
46. Catella-Lawson, F., Crofford, L. J. (2001) Cyclooxygenase inhibition and thrombogenicity. Am. J. Med. 110: 28S-32S
47. Catella-Lawson, F., McAdam, B., Morrison, B. W., Kapoor, S., Kujubu, D., Antes, L., Lasseter, K. C., Quan, H., Gertz, B.J., FitzGerald, G. A. (1999) Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J. Pharmacol. Exp. Ther. 289: 735-741
48. Catella-Lawson, F., Reilly, M. P., Kapoor, S. C., Cucchiara, A. J., DeMarco, S., Tournier, B., Vyas, S. N., FiztGerald, G. A. (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N. Engl. J. Med. 345: 1809-1817
49. Chan, C.-C, Boyce, S., Brideau, C., Charleson, S., Cromlish, W., Ethier, D., Evans, J., Ford-Hutchinson, A. W., Forrest, M. J., Gauthier, J. Y., Gordon, R., Gresser, M., Guay, J., Kargman, S., Kennedy, B., Leblanc, Y., Leger, S., Mancini, J., O'Neill, G. P., Ouellet, M., Patrick, D., Percival, M. D., Perrier, H., Prasit, P., Rodger, I., Tagari, P., Therien, M., Vickers, P., Visco, D., Wang, Z., Webb, J., Wong, E., Xu, L.-J., Young, R. N., Zamboni, R., Riendeau, D. (1999) Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: A potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J. Pharmacol. Exp. Ther. 290: 551-560
50. Chang, D. J., Fricke, J. R., Bird, S. R., Bohidar, N. R., Dobbins, T. W., Geba, G. P. (2001) Rofecoxib versus codeine/acetaminophen in postoperative dental pain: A double-blind, randomized, placebo- and active comparator-controlled clinical trial. Clin. Ther. 23: 1446-1455
51. Chang, D. J., Desjardins, P. J., Chen, E., Polis, A. B., McAvoy, M., Mockoviak, S. H., Geba, G. P. (2002) Comparison of the analgesic efficacy of rofecoxib and enteric-coated diclofenac sodium in the treatment of postoperative dental pain: A randomized, placebo-controlled clinical trial. Clin. Ther. 24: 490-503
52. Chavez-Eng, C. M., Constanzer, M. L., Matuszewski, B. K. (2000) Determination of rofecoxib (MK-0966), a cyclooxygenase-2 inhibitor, in human plasma by high-performance liquid chromatography with tandem mass spectrometric detection. J. Chromatogr. B Biomed. Sci. Appl. 748: 31-39
53. Chavez-Eng, C. M., Constanzer, M. L., Matuszewski, B. K. (2002) High-performance liquid chromatographic-tandem mass spectrometric evaluation and determination of stable isotope labeled analogs of rofecoxib in human plasma samples from oral bioavailability studies. J. Chromatogr. B Biomed. Sci. Appl. 767: 117-129
54. Chen, F.-J., Patel, M. V. (2001) Clear Oil-Containing Pharmaceutical Compositions. Lipocaine Inc., Salt Lake City, UT. US 6267985
55. Cheng, H. F., Wang, J. L., Zhang, M. Z., Miyazaki, Y., Ishikawa, I., McKanna, J. A., Harris, R. C. (1999) Angiotensin II stimulates renal cortical cyclooxygenase-2 expression. J. Clin. Invest. 103: 953-961
56. Chiolero, A., Wurzner, G., Burnier, M. (2000) Selective inhibitors of type 2 cyclooxygenase: Less renal effects than the classical non-steroidal antiinflammatory agents. Nephrologie 21: 425-430
57. Cleland, L. G., James, M. J., Stamp, L. K., Penglis, P. S. (2001) COX-2 inhibition and thrombotic tendency: A need for surveillance. Med. J. Aust. 175: 214-217
58. Crofford, L. J. (2002) Specific cyclooxygenase-2 inhibitors: What have we learned since they came into widespread clinical use? Curr. Opin. Rheumatol. 14: 225-230
59. Cronstein, B. N. (2002) Cyclooxygenase-2-selective inhibitors: Translating pharmacology into clinical utility. Cleve. Clin. J. Med. 69: SI13-SI19
60. Daniels, S., Morrison, B. W., Cantu, N., Sandler, M., Mccrary, L., Kotey, P., Seidenberg, B. (1999) Dose ranging trial of the effect of MK-0966 in primary dysmenorrhoea. (abstract) Clin. Pharmacol. Ther. 65: 118, PI-6
61. Day, R., Morrison, B., Luza, A., Castaneda, O., Strusberg, A., Nahir, M., Helgetveit, K. B., Kress, B., Daniels, B., Bolognese, J., Krupa, D., Seidenberg, B., Ehrich, E. (2000) A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/ibuprofen comparator study group. Arch. Intern. Med. 160: 1781-1787
62. De La Serna Higuera, C., Rodriguez-Gomez, S. J., Martin, Arribas, M. I., Martinez Moreno, J. (2002) Rofecoxib induced upper gastrointestinal bleeding. Med. Clin. (Barc) 118: 238
63. Depré, M., Ehrich, E., Van Hecken, A., De Lepeleire, I., Dallob, A., Wong, P., Porras, A., Gertz, B.J., De Schepper, P. J. (2000) Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans. Eur. J. Clin. Pharmacol. 56: 167-174
64. Deray, G. (2001) Renal tolerance of selective inhibitors of cyclooxygenase type 2. Presse Med. 30: 1507-1512
65. Detora, L. M., Krupa, D., Bolognese, J., Sperling, R. S., Ehrich, E. W. (2001) Rofecoxib shows consistent efficacy in osteoarthritis clinical trials, regardless of specific patient demographic and disease factors. J. Rheumatol. 28: 2494-2503
66. DeWitt, D. L. (1991) Prostaglandin endoperoxide synthase: Regulation of enzyme expression. Biochim. Biophys. Acta 111: 445-454
67. Dicker, A. P., Williams, T. L., Grant, D. S. (2001) Targeting angiogenic processes by combination rofecoxib and ionizing radiation. Am. J. Clin. Oncol. 24: 438-442
68. Dinchuk, J. E., Carr, B.D., Focht, R. J., Johnston, J. J., Jaffer, B. D., Covington, M. B., Contel, N. R., Eng, V. M., Collins, R. J., Czerniak, P. M., Gorry, S. A., Trzaskos, J. M. (1995) Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase-2. Nature 378: 406-409
69. Eberhart, C. E., Coffey, R. Y., Radhica, A., Giardello, F. M., Ferrenbach, S., DuBois, R. N. (1994) Up regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107: 1183-1188
70. Ehrich, E. W., Dallob, A., De Lepeleire, I., Van Hecken, A., Riendeau, D., Yuan, W., Porras, A., Wittreich, J., Seibold, J. R., De Schepper, P., Mehlisch, D. R., Gertz, B. J. (1999a) Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin. Pharmacol. Ther. 65: 336-347
71. Ehrich, E. W., Schnitzer, T. J., McIlwain, H., Levy, R., Wolfe, F., Weisman, M., Zeng, Q., Morrison, B., Bolognese, J., Seidenberg, B., Gertz, B. J. (1999b) Effect of specific COX-2 inhibition in osteoarthritis of the knee: A 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib osteoarthritis pilot study group. J. Rheumatol. 26: 2438-2447
72. Ehrich, E. W., Davies, G. M., Watson, D. J., Bolognese, J. A., Seidenberg, B. C., Bellamy, N. (2000) Minimal perceptible clinical improvement with the Western Ontarior and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis. J. Rheumatol. 27: 2635-2641
73. Ehrich, E. W., Bolognese, J. A., Watson, D. J., Kong, S. X. (2001) Effect of rofecoxib therapy on measures of health-related quality of life in patients with osteoarthritis. Am. J. Manag. Care 7: 609-616
74. Enrique, E., Cistero-Bahima, A., San Miguel-Moncin, M. M., Alonso, R. (2000) Rofecoxib should be tried in NSAID hypersensitivity. Allergy 55: 1090
75. Faour, J., Coppari, M. A. (2001) Osmotic Device Within an Osmotic Device for Drug Delivery. Laboratories Phoenix U.S.A., Inc., USA. WO 2001051036, US 2002035357
76. FDA (1999a) NDA approvals for calender year 1999 of December, 1999. US FDA, Center for Drug Evaluation and Research, Rockville, MD. http://www.fda.gov/cder/rdmt/ndaaps99cy.htm (accessed 12 April 2003)
77. FDA (1999b) Listing of approved oncology drugs with approved indications. http://www.fda.gov/cder/cancer/drugslistframe.htm, (accessed 24 April 2003)
78. FDA (2002) Drug approvals for April, 2002. US FDA, Center for Drug Evaluation and Research, Rockville, MD. http://www.fda.gov/cder/da/da0402.htm (accessed 12 April 2003)
79. FDA (2002b) Information on Vioxx®. US FDA, Center for Drug Evaluation and Research, Rockville, MD. http://www.fda.gov/cder/foi/label/2002/21042s71bl.pdf (accessed 11 April 2003)
80. Fendrick, A. M. (2002) Developing an economic rationale for the use of selective COX-2 inhibitors for patient at risk for NSAID gastropathy. Cleve. Clin. J. Med. 69 (Suppl. 1): SI59-SI64
81. Ferencik, M., Novak, M., Rovensky, J., Rybar, I. (2001) Alzheimer's disease, inflammation and non-steroidal antiinflammatory drugs. Bratisl. Lek. Listy. 102: 123-132
82. Ferguson, S., Hebert, R. L., Laneuville, O. (1999) NS-398 upregulates constitutive cyclooxygenase-2 expression in the M-1 cortical collecting duct cell line. J. Am. Soc. Physiol. 280: F43-F45
83. Ferreri, N. R., Shao-Jian, A., McGiff, J. (1999) Cyclooxygenase-2 expression and function in the medullary thick ascending limb. Am. J. Physiol. (Renal Physiol.) 277: F360-F368
84. FitzGerald, G. A., Patrono, C. (2001) The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med. 345: 433-442
85. FitzGerald, G. A., Cheng, Y., Austin, S. (2001) COX-2 inhibitors and the cardiovascular system. Clin. Exp. Rheumatol. 19 (Suppl. 25): S31-S36
86. Foral, P. A., Wilson, A. F., Nystrom, K. K. (2002) Gastrointestinal bleeds associated with rofecoxib. Pharmacotherapy 22: 384-386
87. Forgione, P., Wilson, P. D., Fallis, A. G. (2000) Magnesium mediated carbometallation of propargyl alcohols: Direct routes to furans and furanones. Tetrahedron Lett. 41: 17-20
88. Fraley, M. E., Hartman, G. D., Hungate, R. W. (2002) Tyrosine Kinase Inhibitors. Merck & Co., Inc., Rahway, NJ. US 6420382
89. Frankish, H. (2002) Why do COX-2 inhibitors increase risk of cardiovascular events? Lancet 359: 1410
90. Freedman, G. M., Kreitzer, J. M., Badola, R. (2002) Rofecoxib-associated upper gastrointestinal bleed: A case report. Mt Sinai. J. Med. 69: 105-106
91. Freitas, J., Farricha, V., Nascimento, I., Borralho, P., Parames, A. (2002) Rofecoxib: A possible cause of acute colitis. J. Clin. Gastroenterol. 34: 451-453
92. Fricke, J., Morrison, B. W., Skip Fite, R. N., Sandler, M., Yuan, W., Howard, C., Seidenberg, B. (1999) MK-966 versus naproxen sodium 550mg in post-surgical dental pain. (abstract) Clin. Pharmacol. Ther. 65: 119, PI-7
93. Fries, J. F. (1991) NSAID gastropathy: The second most deadly rheumatic disease? Epidemiology and risk appraisal. J. Rheumatol. 18 (Suppl. 28): 6-10
94. Frishman, W. H. (2002) Effects of nonsteroidal antiinflammatory drug therapy on blood pressure and peripheral edema. Am. J. Cardiol. 89: 18D-25D
95. Froelich, J. C., Wilson, T. W., Sweetman, B. J., Smigel, J. M., Nies, A. S., Carr, K., Watson, J. T., Oates, J. A. (1975) Urinary prostaglandins: Identification and origin. J. Clin. Invest. 55: 763-770
96. Frost, P., Discafani-Marro, C. M. (2000) Method of Treating or Inhibiting Colonic Polyps and Colorectal Cancer. American Cyanamid Company, Madison, NJ US 6432979
97. Garner, S., Fidan, D., Frankish, R., Judd, M., Towheed, T., Wells, G., Tugwell, P. (2000) Rofecoxib for the treatment of rheumatoid arthritis (Cochrane Review). Cochrane Database Syst. Rev. 3: CD003685
98. Garnett, W. R. (2001) Clinical implications of drug interactions with coxibs. Pharmacotherapy 21: 1223-1232
99. Geba, G. P., Polis, A. B., Dixon, M. E., Dobbins, T. W., Rush J. E., Weir, M. (2001) Comparative blood pressure effects of rofecoxib, celecoxib, and placebo in patients with osteoarthritis: A randomized controlled trial. (abstract) Ann. Rheum. Dis. 60 (Suppl. 1): 236, SAT0095
100. Geba, G. P., Weaver, A. L., Polis, A. B., Dixon, M. E., Schnitzer, T. J. (2002) Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: A randomized trial. JAMA 287: 64-71
101. Gertz, B. J., Krupa, D., Bolognese, J. A., Sperling, R. S., Reicin, A. (2002) A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal antiinflammatory agents. Curr. Med. Res. Opin. 18: 82-91
102. Graham, G. G., Graham, R. I., Day, R. O. (2002) Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib and acetaminophen (paracetamol). Curr. Pharm. Des. 8: 1063-1075
103. Greenberg, H. E., Gottesdiener, K., Huntington, M., Wong, P., Larson, P., Wildonger, L., Gillen, L., Dorval, E., Waldman, S. A. (2000) A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers. J. Clin. Pharmacol. 40: 1509-1515
104. Gretzer B., Mariric, N., Respondek, M., Schuligoi R., Peskar, B. M. (2001) Effects of specific inhibition of cyclo-oxygenase-1 and cyclo-oxygenase-2 in the rat stomach with normal mucosa and after acid challenge. Br. J. Pharmacol. 132: 1565-1573
105. Griswold D. E., Adams, J. L. (1996) Constitutive cyclooxygenase (COX-1) and inducible cyclooxygenase (COX-2): Rationale for selective inhibition and progress to date. Med. Res. Rev. 16: 181-206.
106. Guo, J., Cho, C., Lam Liu, E., Choy, H., Wang, J., Leung Koo, M. (2002) Antiangiogenic effect of a highly selective cyclooxygenase-2 inhibitor on gastric ulcer healing in rats. Toxicol. Appl. Pharmacol. 184: 41
107. Halpin, R. A., Geer, L. A., Zhang, K. E., Marks, T. M., Dean, D. C., Jones, A. N., Melillo, D., Doss G., Vyas, K. P. (2000) The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs. Drug Metab. Dispos. 28: 1244-1254
108. Halpin, R. A., Porras, A. G., Geer, L. A., Davis, M. R., Cui, D., Doss, G. A., Woolf, E., Musson, D., Matthews, C., Mazenko, R., Schwartz, J. I., Lassester, K. C., Vyas, K. P., Baillie, T. A. (2002) The disposition and metabolism of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in human subjects. Drug Metab. Dispos. 30: 684-693
109. Harris, R. C. (2002) Cyclooxygenase-2 inhibition and renal physiology. Am. J. Cardiol. 89: 10D-17D
110. Harris, R. C., McKanna, J. A., Akai, Y., Jacobson, H. R., Dubois, R. N., Breyer, M. D. (1994) Cyclooxygenase-2 is associated with the macula densa of kidney and increases with salt restriction. J. Clin. Invest. 94: 2504-2510
111. Hartman, R., Clausen, A., Mao, B., Abrahim, A., Crocker, L., Ge, Z. (2002) Investigation of the photostability of two COX-2 inhibitors, rofecoxib and etoricoxib, by HPLC using forced degradation. 224th ACS National Meeting, Boston, MA, US. (abstract) ANYL-074
112. Hawkey, C. J. (1999) COX-2 inhibitors. Lancet 353: 307-314
113. Hawkey, C. J. (2001) Gastrointestinal safety of COX-2 specific inhibitors. Gastroenterol. Clin. North Am. 30: 921-936
114. Hawkey, C. J., Laine, L., Simon, T., Beaulieu, A., Maldonado-Cocco, J., Acevedo, C., Shahane, A., Quan, H., Bolognese, J., Mortensen, E. (2000) Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial. The rofecoxib osteoarthritis endoscopy multinational study group. Arthritis Rheum. 43: 370-377
115. Hawkey, C. J., Jackson, L., Harper, S. E., Simon, T. J., Mortensen, E., Lines, C. R. (2001a) Review article: The gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans. Aliment. Pharmacol. Ther. 15: 1-9
116. Hawkey, C. J., Laine, L., Harper, S. E., Quan, H. U., Bolognese, J. A., Mortensen, E. (2001b) Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials. Aliment. Pharmacol. Ther. 15: 1593-1601
117. Hay, E., Derazon, H., Bukish, N., Katz, L., Kruglyakov, I., Armoni, M. (2002) Fatal hyperkalemia related to combined therapy with a COX-2 inhibitor, ACE inhibitor and potassium rich diet (1). J. Emerg. Med. 22: 349-352
118. Hillson, J. L., Furst, D. E. (2000) Rofecoxib. Expert. Opin. Pharmacother. 1: 1053-1066
119. Hinrichs, R., Ritzkowsky, A., Hunzelmann, N., Krieg, T., Scharffetter-Kochanek, K. (2001) Rofecoxib as an alternative in aspirin hypersensitivity. Allergy 56: 789
120. Hirsh, J. C., Midha, K. K., Hirsh, M., Lo, W.-Y. (2000) Multi-layered pharmaceutical composition for both intraoral and oral administration with polymeric coatings. Peirce Management, LLC, USA. Eur. Pat. Appl. EP 1260216
121. Ho, L. L., Brighton, T. (2002) Warfarin, antiplatelet drugs and their interactions. Aust. Prescriber 25: 81-85
122. Hochberg, M. C. (2001) What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective. Clin. Exp. Rheumatol. 19 (6 Suppl 25): S15-S22
123. Hocherl, K., Kammerl, M. C., Schumacher, K., Endemann, D., Grobecker, H. F., Kurtz, A. (2002a) Role of prostanoids in regulation of the renin-angiotensin-aldosterone system by salt intake. Am. J. Physiol. Renal Physiol. 283: F294-F301
124. Hocherl, K.,. Endemann, D., Kammerl, M. C., Grobecker, H. F., Kurtz, A. (2002b) Cyclo-oxygenase-2 inhibition increases blood pressure in rats. Br. J. Pharmacol. 136: 1117-1126
125. Huang, J. J., Taguchi, A., Hsu, H., Andriole, G. L., Kurz, A. (2001) Preoperative oral rofecoxib does not decrease postoperative pain or morphine consumption in patients after radical prostatectomy: A prospective, randomized, double-blinded, placebo-controlled trial. J. Clin. Anesth. 13: 94-97
126. Hunt, R. H., Bowen, B., Mortensen, E. R., Simon, T. J., James, C., Cagliola, A., Quan, H., Bolognese, J. A. (2000) A randomized trial measuring faecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects. Am. J. Med. 109: 201-206
127. Hunt, R. H., Barkun, A. N., Baro, D., Bombardier, C., Bursey, F. F., Marshall, J. R., Morgan, D. G., Pare, P., Thompson, A. B., Whittaker, J. S. (2002) Recommendations for the appropriate use of antiinflammatory drugs in the era of the coxibs: Defining the role of gastroprotective agents. Can. J. Gastroenterol. 16: 231-240
128. Husni, M. E., Solomon, D. H., Colbyn, J. S. (2002) Selective COX-2 inhibitors: Towards defining their appropriate clinical role. J. Clin. Outcome Management 9: 265-268
129. Huster, D., Schubert, C., Berr, F., Mossner, J., Caca, K. (2002) Rofecoxib-induced cholestatic hepatitis: Treatment with molecular adsorbent recycling system (MARS). J. Hepatol. 37: 413
130. Jackson, L. M., Hawkey, C. J. (2000) COX-2 selective nonsteroidal antiinflammatory drugs: Do they really offer any advantages? Drugs 59: 1207-1216
131. Jaeschke, R., Gajewski, P., Brozek, J. (2002) Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 106: e18
132. Jain, N. K., Patil, C. S., Kulkarni, S. K., Singh, A. (2002) Modulatory role of cyclooxygenase inhibitors in aging- and scopolamine or lipopolysaccharide-induced cognitive dysfunction in mice. Behav. Brain Res. 133: 369-376
133. Jamali, F., Sattari, S. (2000) High performance liquid chromatographic determination of cyclooxygenase II inhibitor rofecoxib in rat and human plasma. J. Pharm. Pharm. Sci. 3: 312-317
134. Jensen, B. L., Kurtz, A. (1997) Differential regulation of renal cyclooxygenase mRNA by dietary salt intake. Kidney Int. 52: 1242-1249
135. Kalgutkar, A. S., Zhao, Z. (2001) Discovery and design of selective cyclooxygenase-2 inhibitors as non-ulcerogenic, antiinflammatory drugs with potential utility as anti-cancer agents. Curr. Drug Targets 2: 70-106
136. Kammerl, M. C., Nsing, R. M., Schweda, F., Endemann, D., Stubanus, M., Kees, F., Lackner, K. J., Fischereder, M., Kramer, B. K. (2001a) Low sodium and furosemide-induced stimulation of the renin system in man is mediated by cyclooxygenase 2. Clin. Pharmacol. Ther. 70: 468-474
137. Kammerl, M. C., Nüsing, R. M., Richthammer, W., Kramer, B. K., Kurtz, A. (2001b) Inhibition of COX-2 counteracts the effects of diuretics in rats. Kidney Int. 60: 1684-1691
138. Kaplan-Machlis, B., Klostermeyer, B. S. (1999) The cycloxoxygenase-2 inhibitors: Safety and effectiveness. Ann. Pharmacother. 33: 979-988
139. Karali, T. T., Kontny, M. J., Le T. T. (2002) Pharmacia Corporation, USA. WHO 2002015886
140. Kargman, S., Charlson, S., Cartwright, M., Frank, J., Riendeau, D., Mancini, J., Evans, J., O'Neill, G. (1996) Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology 111: 445-454
141. Kato, S., Takeuchi, K. (2002) Alteration of gastric ulcerogenic and healing responses in rats with adjuvant-induced arthritis. Jpn. J. Pharmacol. 89: 1-6
142. Kato, M., Nishida, S., Kitasato, H., Sakata, N., Kawai, S. (2001) Cyclooxygenase-1 and cyclooxygenase-2 selectivity of nonsteroidal antiinflammatory drugs: Investigation using human peripheral monocytes. J. Pharm. Pharmacol. 53: 1679-1685
143. Katz, N. (2002) The impact of pain management on quality of life. J. Pain Symptom Manage. 24 (Suppl. 1): S38
144. Kaufman, W. E., Worley, P. F., Pegg, J., Bremer, M., Iskason, P. (1996) COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc. Natl Acad. Sci. USA 93: 2317-2321
145. Kaur, C., Sarkar, R., Kanwar, A. J. (2001) Fixed drug eruption to rofecoxib with cross-reactivity to sulfonamides. Dermatology 203: 351
146. Kaur, B. S., Khamnehei, N., Iravani, M., Namburu, S. S., Lin, O., Triadafilopoulos, G. (2002) Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's oesophagus. Gastroenterology 123: 60-67
147. Kelkar, P. S., Butterfield, J . H., Teaford, H. G. (2001) Urticaria and angioedema from cyclooxygenase-2 inhibitors. J. Rheumatol. 28: 2553-2554
148. Kiang Y. H., Xu W., Kaufman M. J. (2003) Ab initio structure determination of rofecoxib from powder diffraction data using molecular packing analysis method and direct space method. Int. J. Pharm. 252: 213-223
149. Kirtikara, K., Swangkul, S., Ballou, L. R. (2001) The analysis of nonsteroidal antiinflammatory drug selectivity in prostaglandin G/H synthase (PGHS)-null cells. Inflamm. Res. 50: 327-332
150. Kitahara, M., Eitner, F., Ostendorf, T., Kunter, U., Janssen, U., Westenfeld, R., Matsui, K., Kerjaschki, D., Floege, J. (2002) Selective cyclooxygenase-2 inhibition impairs glomerular capillary healing in experimental glomerulonephritis. J. Am. Soc. Nephrol. 13: 1261-1270
151. Kömhoff, M., Gröne, H.-J., Klein, T., Seyberth, H. W., Nsing, R. M. (1997) Localization of cyclooxygenase-1 and -2 in adult and foetal human kidney: Implication for renal function. Am. J. Physiol. 272: F460-F468
152. Kömhoff, M., Wang, J. L., Cheng, H. F., Lagenbach, R., McKanna, J. A., Harris, R. A., Breyer, M. D. (2000) Cyclooxygenase-2 selective inhibitors impair glomerulogenesis and renal cortical development. Kidney Int. 57: 414-422
153. Konstam, M. A., Weir, M. R. (2002) Current perspective on the cardiovascular effects of coxibs. Cleve. Clin. J. Med. 69 (Suppl. 1): SI47-SI52
154. Konstam, M. A., Weir, M. R., Reicin, A., Shapiro, D., Sperling, R. S., Barr, E., Gertz, B. J. (2001) Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 104: 2280-2288
155. Krishna Reddy, K. V., Moses Babu, J., Dubey, P. K., Chandra Sekhar, B., Om Reddy, G., Vyas, K. (2002) Isolation and characterisation of process-related impurities in rofecoxib. J. Pharm. Biomed. Anal. 29: 355-360
156. Krymchantowski, A., Barbosa, J. (2002) Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: An open label pilot study. Cephalalgia 22: 309-312
157. Kumar, N. P., Wild, G., Ramasamy, K. A., Snape, J. (2002) Fatal haemorrhagic pulmonary oedema and associated angioedema after the ingestion of rofecoxib. Postgrad. Med. J. 78: 439-440
158. Laine, L. (2002) Gastrointestinal safety of coxibs and outcomes studies: What's the verdict? J. Pain Symptom Manage. 23 (Suppl. 4): S5-S10
159. Laine, L., Harper, S., Simon, T., Bath, R., Johanson, J., Schwartz, H., Stern, S., Quan, H., Bolognese, J. (1999) A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib osteoarthritis endoscopy study group. Gastroenterology 117: 776-783
160. Lanas, A. (2002) Clinical experience with cyclooxygenase-2 inhibitors. Rheumatology 41 (Suppl. 1): 16-22
161. Langman, M. J., Jensen, D. M., Watson, D. J., Harper, S. E., Zhao, P. L., Quan, H., Bolognese, J. A., Simon, T. J. (1999) Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 282: 1929-1933
162. Lanza, F. L., Rack, M. F., Simon, T. J., Quan, H., Bolognese, J., Hoover, M. E., Wilson, F. R., Harper, S. E. (1999) Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen. Aliment. Pharmacol. Ther. 13: 761-767
163. Laudanno, O. M., Cesolari, J. A., Esnarriaga, J., Rista, L., Piombo, G., Maglione, C., Aramberry, L., Sambrano, J., Godoy, A., Rocaspana, A. (2001) Gastrointestinal damage induced by celecoxib and rofecoxib in rats. Dig. Dis. Sci. 46: 779-784
164. Lew, J. I., Guo, Y., Kim, R. K., Vargish, L., Michelassi, F., Arenas, R. B. (2002) Reduction of intestinal neoplasia with adenomatous polyposis coli gene replacement and cox-2 inhibition is additive. J. Gastrointest. Surg. 6: 563-568
165. Lim, H., Paria, B. C., Das, S. K., Dinchuk, J. E., Langenbach, R., Trzaskos, J. M., Dey, S. K. (1997) Multiple female reproductive failures in cyclooxygenase 2 deficient mice. Cell 91: 197-208
166. Loewen, P. S. (2002) Review of the selective COX-2 inhibitors celecoxib and rofecoxib: Focus on clinical aspects. Can. J. Emerg. Med. 4: 1-11
167. Lundmark, J., Gunnarsson, T., Bengtsson, F. (2002) A possible interaction between lithium and rofecoxib. Br. J. Clin. Pharmacol. 53: 403-404
168. Luong, C., Miller, A., Barnett, J., Chow, J., Ramasha, C., Browner, M. F. (1996) The structure of human cyclooxygenase-2; conservation and flexibility of the NSAID binding site. Nat. Struct. Biol. 3: 927-933
169. Mahadevan, U., Loftus, E. V., Jr. Tremaine, W. J., Sandborn, W. J. (2002) Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am. J. Gastroenterol. 97: 910-914
170. Malmstrom, K., Daniels, S., Kotey, P., Seidenberg, B. C., Desjardins, P. J. (1999) Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: A randomized, placebo- and active-comparator-controlled clinical trial. Clin. Ther. 21: 1653-1663
171. Malmstrom, K., Fricke, J. R., Kotey, P., Kress, B., Morrison, B. (2002) A comparison of rofecoxib versus celecoxib in treating pain after dental surgery: A single-center, randomized, double-blind, placebo- and active-comparator- controlled, parallel-group, single-dose study using the dental impaction pain model. Clin. Ther. 24: 1549-1560
172. Mao, B., Abrahim, A., Ge, Z., Ellison, D. K., Hartman, R., Prabhu, S. V., Reamer, R. A., Wyvratt, J. (2002) Examination of rofecoxib solution decomposition under alkaline and photolytic stress conditions. J. Pharm. Biomed. Anal. 28: 1101-1113
173. Marshall, J. K., Pellissier, J. M., Attard, C. L., Kong, S. X., Marentette, M. A. (2001) Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective. Pharmacoeconomics 19: 1039-1049
174. Martin-Garcia, C., Hinojosa, M., Berges, P., Camacho, E., Garcia-Rodriguez, R., Alfaya, T., Iscar, A. (2002) Safety of a cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma. Chest 121: 1812-1817
175. Matheson, A. J., Figgitt, D. P. (2001) Rofecoxib: A review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis. Drugs 61: 833-865
176. Matthews, C. Z., Woolf, E. J., Matuszweski, B. K. (2002) Improved procedure for the determination of rofecoxib in human plasma involving 96-well solid-phase extraction and fluorescence detection. J. Chromatogr. A 949: 83-89
177. Mayan, H., Gurevitz, O., Farfel, Z. (2002) Successful treatment by cyclooxygenase-2 inhibitor of refractory hypokalemia in a patient with Gitelman's syndrome. Clin. Nephrol. 58: 73-76
178. McGeer, P. L., McGeer, E. G. (1995) The inflammatory response system of brain: Implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res. Rev. 21: 195-218
179. McMurray, R. W., Hardy, K. J. (2002) Cox-2 inhibitors: Today and tomorrow. Am. J. Med. Sci. 323: 181-189
180. Meade, E. A., Smith, W. L., DeWitt, D. L. (1993) Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal antiinflammatory drugs. J. Biol. Chem. 268: 6610-6614
181. Mehlisch, D. R., Mills, S., Sandler, M., Yuan, W., Dury, W., Ehrich, E., Seidenberg, B., Morrison, B. (1998) Ex vivo assay of COX-2 inhibition predicts analgesic efficacy in post-surgical dental pain with MK-966. (abstract) Clin. Pharmacol. Ther. 63: 139, PI-8
182. Merck & Co., Inc. (1998) VIOXX (Rofecoxib Tablets and Oral Suspension). Merck & Co., Inc., Whitehouse Station, New Jersey, USA
183. Meyer, R. (2002) Rofecoxib reduces perioperative morphine consumption for abdominal hysterectomy and laparoscopic gastric banding. Anaesth. Intensive Care 30: 389-390
184. Miralpeix, M., Camacho, M., Lopez-Belmonte, J., Canalias, F., Beleta, J., Palacios, J. M., Vila, L. (1997) Selective induction of cyclooxygenase-2 activity in the permanent human endothelial cell line HUV-EC-C: Biochemical and pharmacological characterization. Br. J. Pharmacol. 121: 171-180
185. Mitchell, J. A., Akaraserennont, P., Thiemermann, C., Flower, R. J., Vane, J. R. (1994) Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc. Natl Acad. Sci. USA 90: 11693-11697
186. Mizuno, H., Sakamoto, C., Matsuda, K., Wada, K., Hahida, T., Noguabi, H., Akamatsu, T., Kasuga, M. (1997) Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by specific antagonist delays healing in mice. Gastroenterology 112: 387-397
187. Moore, P. A., Hersh, E. V. (2001) Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice. J. Am. Dent. Assoc. 132: 451-456
188. Morrison, B. W., Christensen, S., Yuan, W., Brown, J., Amlani, S., Seidenberg, B. (1999a) Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: A randomized, controlled trial. Clin. Ther. 21: 943-953
189. Morrison, B. W., Daniels, S. E., Kotey, P., Cantu, N., Seidenberg, B. (1999b) Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhoea: A randomized controlled trial. Obstet. Gynecol. 94: 504-508
190. Morrison, B. W., Fricke, J., Brown, J., Yuan, W., Kotey, P., Mehlisch, D. (2000) The optimal analgesic dose of rofecoxib: Overview of six randomized controlled trials. J. Am. Dent. Assoc. 131: 1729-1737
191. Mukherjee, D. (2002) Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events. Biochem. Pharmacol. 63: 817-821
192. Mukherjee, D., Nissen, S. E., Topol, E. J. (2001) Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286: 954-959
193. Murpani, D., Malik, R. (2002) Process for the Preparation of a Fast Dissolving Dosage Form. Ranbaxy Laboratories Ltd., India. WO 2002047607
194. Naesdal, J., Wilson, I. (2001) Gastro-duodenal protection in an era of cyclo-oxygenase-2-selective nonsteroidal antiinflammatory drugs. Eur. J. Gastroenterol. Hepatol. 13: 1401-1406
195. Nettis, E., Di, P. R., Ferrannini, A., Tursi, A. (2002) Tolerability of rofecoxib in patients with cutaneous adverse reactions to nonsteroidal antiinflammatory drugs. Ann. Allergy Asthma Immunol. 88: 331-334
196. Niccoli, L., Bellino, S., Cantini, F. (2002) Renal tolerability of three commonly employed non-steroidal antiinflammatory drugs in elderly patients with osteoarthritis. Clin. Exp. Rheumatol. 20: 201-207
197. Noble, S. L,, King, D. S., Olutade, J. I. (2000) Cyclooxygenase-2 enzyme inhibitors: Place in therapy. Am. Fam. Physician. 61: 3669-3676
198. Noroian, G., Clive, D. (2002) Cyclo-oxygenase-2 inhibitors and the kidney: A case for caution. Drug Saf. 25: 165-172
199. Ofran, Y., Bursztyn, M., Ackerman, Z. (2001) Rofecoxib-induced renal dysfunction in a patient with compensated cirrhosis and heart failure. Am. J. Gastroenterol. 96: 1941
200. Olszynski, W. P., Sylwestrowicz, T. A., Pylypchuk, G. B., Regler, L. D. (2002) Coxibs in clinical practice: Towards a Saskatchewan consensus. In: RxFiles; The RxFiles Academic Program. Saskatoon City Hospital, Saskatoon, SK, Canada available at www.sdh.sk.ca/rxfiles/acrobat/coxibs2002-consensus-header.pdf (accessed 11 April 2003)
201. Oshima, M., Murai, N., Kargman, S., Arguello, M., Luk, P., Kwong, E., Taketo, M. M., Evans, J. F. (2001) Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res. 61: 1733-1740
202. Osterhaus, J. T., Burke, T. A., May, C., Wentworth, C., Whelton, A., Bristol, S. (2002) Physician-reported management of edema and destabilized blood pressure in cyclooxygenase-2-specific inhibitor users with osteoarthritis and treated hypertension. Clin. Ther. 24: 969-989
203. Ouellet, M., Riendeau, D., Percival, M. D. (2001) A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin. Proc. Natl Acad. Sci. USA 98: 14583-14588
204. Pacor, M. L., Di Lorenzo, G., Biasi, D., Barbagallo, M., Corrocher, R. (2002) Safety of rofecoxib in subjects with a history of adverse cutaneous reactions to aspirin and/or non-steroidal antiinflammatory drugs. Clin. Exp. Allergy 32: 397-400
205. Pall, M., Friden, B. E., Brannstrom, M. (2001) Induction of delayed follicular rupture in the human by the selective COX-2 inhibitor rofecoxib: A randomized double-blind study. Hum. Reprod. 16: 1323-1328
206. Palmer, R. H. (2001) Discussion on rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production. Gastroenterology 121: 1262-1263
207. Pascucci, R. A. (1999) COX-2-specific inhibition: Implications for clinical practice. J. Am. Osteopath. Assoc. 99 (Suppl. 11): S18-S22
208. Patel, M. V., Chen, F.-J. (2001) Triglyceride-Free Compositions and Methods for Improved Delivery of Hydrophobic Therapeutic Agents. Lipocine, Inc., Salt Lale City, UT. US 6294192
209. Patti, R., Gumired, K., Reddanna, P., Sutton, L. N., Phillips, P. C., Reddy, C. D. (2002) Overexpression of cyclooxygenase-2 (COX-2) in human primitive neuroectodermal tumors: Effect of celecoxib and rofecoxib. Cancer Lett. 180: 13-21
210. Pedros, C., Cereza, G., Laporte, J. R. (2002) First spontaneous reports of adverse reactions to the new selective COX-2 non-steroidal antiinflammatory drugs. Med. Clin. (Barc.) 118: 415-417
211. Perazella, M. A., Tray, K. (2001) Selective cyclooxygenase-2 inhibitors: A pattern of nephrotoxicity similar to traditional nonsteroidal antiinflammatory drugs. Am. J. Med. 111: 64-67
212. Peres, M. F., Silberstein, S. D. (2002) Hemicrania continua responds to cyclooxygenase-2 inhibitors. Headache 42: 530-531
213. Peres, M. F., Zukerman, E. (2000) Hemicrania continua responsive to rofecoxib. Cephalalgia 20: 130-131
214. Peretz, A. (2001) COX-2 inhibitor non-steroidal antiinflammatory drugs, myth or reality? Rev. Med. Brux. 22: A377-A380
215. Peura, D. A. (2002) Gastrointestinal safety and tolerability of nonselective nonsteroidal antiinflammatory agents and cyclooxygenase-2-selective inhibitors. Cleve. Clin. J. Med. 69: (Suppl. 1): SI31-SI39
216. Pickering, A. E., Bridge, H. S., Nolan, J., Stoddart, P. A. (2002) Double-blind, placebo-controlled analgesic study of ibuprofen or rofecoxib in combination with paracetamol for tonsillectomy in children. Br. J. Anaesth. 88: 72-77
217. Picot, D., Loll, P. J., Garavito, R. M. (1994) The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 367: 243-249
218. Quiralte, J., Saenz De San Pedro, B., Florido, J. J. (2002) Safety of selective cyclooxygenase-2 inhibitor rofecoxib in patients with NSAID-induced cutaneous reactions. Ann. Allergy Asthma Immunol. 89: 63-66
219. Radhakrishna, T., Sreenivas Rao, D., Om Reddy, G. (2001) LC determination of rofecoxib in bulk and pharmaceutical formulations. J. Pharm. Biomed. Anal. 26: 617-628
220. Radi, A. (2002) Adsorptive stripping square-wave voltammetric behavior of rofecoxib. Microchemical J. 72: 35-41
221. Rajadhyaksha, V. D., Dahanukar, S. A. (2001) Rofecoxib: A new selective COX-2 inhibitor. J. Postgrad. Med. 47: 77-78
222. Reddy, B. S., Rao, C. V. (2002) Novel approaches for colon cancer prevention by cyclooxygenase-2 inhibitors. J. Environ. Pathol. Toxicol. Oncol. 21: 155-164
223. Reddy, M. N., Murthy, T. K., Shanta Kumar, S. M. (2002) UV and visible spectrophotometeric methods for the determination of rofecoxib. Indian Drugs 39: 39-40
224. Rehman, Q., Sack, K. E. (1999) When to try COX-2-specific inhibitors. Safer than standard NSAIDs in some situations. Postgrad. Med. 106: 95-106
225. Reicin, A., Brown, J., Jove, M., DeAndrade, J. R., Bourne, M., Krupa, D., Walters, D., Seidenberg, B. (2001) Efficacy of single-dose and multidose rofecoxib in the treatment of post-orthopedic surgery pain. Am. J. Orthop. 30: 40-48
226. Reicin, A. S., Shapiro, D., Sperling, R. S., Barr, E., Yu, Q. (2002) Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal antiinflammatory drugs (ibuprofen, diclofenac, and nabumetone). Am. J. Cardiol. 89: 204-209
227. Reinalter, S. C., Jeck, N., Brochhausen, C., Watzer, B., Nusing, R. M., Seyberth, H. W., Komhoff, M. (2002) Role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome. Kidney Int. 62: 253-260
228. Reitblat, T., Zamir, D., Estis, L., Priluk, R., Drogenikov, T., Viskoper, J. R. (2002) The different patterns of blood pressure elevation by rofecoxib and nabumetone. J. Hum. Hypertens. 16: 431-434
229. Rekha, K. S., Vyas, K., Raju, C. M. H., Chandrashekhar, B., Reddy, G. O. (2000) Vioxx, a COX-II inhibitor. Acta Crystallogr. Sect. C Cryst. Struct. Commun. 56: e68
230. Reuben, S. S., Connelly, N. R. (2000) Postoperative analgesic effects of celecoxib or rofecoxib after spinal fusion surgery. Anesth. Analg. 91: 1221-1225
231. Reuben, S. S., Bhopatkar, S., Maciolek, H., Joshi, W., Sklar, J. (2002a) The preemptive analgesic effect of rofecoxib after ambulatory arthroscopic knee surgery. Anesth. Analg. 94: 55-59
232. Reuben, S. S., Fingeroth, R., Krushell, R., Maciolek, H. (2002b) Evaluation of the safety and efficacy of the perioperative administration of rofecoxib for total knee arthroplasty. J. Arthroplasty 17: 26-31
233. Ristimaki, A., Honkanen, H., Jaukala, H., Sepponen, P., Harkonen, M. (1997) Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 57: 1276-1280
234. Robertson, E. P. (1998) Dominance of cyclooxygenase-2 in the regulation of pancreatic islet prostaglandin synthesis. Diabetes 47: 1379-1383
235. Rocha, J. L., Fernandez-Alonso, J. (2001) Acute tubulointerstitial nephritis associated with the selective COX-2 enzyme inhibitor, rofecoxib. Lancet 357: 1946-1947
236. Rodrigues, A. D., Halpin, R. A., Geer, L. A., Cui, D., Woolf, E. J., Matthews, C. Z., Gottesdiener, K. M., Larson, P. J., Lasseter, K. C., Agrawal, N. G. B. (2003) Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers. Drug Metab. Dispos. 31: 224-232
237. Roth, S. H. (1986) Nonsteroidal antiinflammatory drug gastropathy: We started it - Can we stop it? Arch. Intern. Med. 146: 1075-1076
238. Saag, K., D. Van Der Heijde, D., Fisher, C., Samara, A., DeTora, L., Bolognese, J., Sperling, R., Daniels, B. (2000) Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal antiinflammatory drugs: A 6-week and a 1-year trial in patients with osteoarthritis. Osteoarthritis studies group. Arch. Fam. Med. 9: 1124-1134
239. Sanchez Borges, M., Capriles-Hulett, A., Caballero-Fonseca, F., Perez, C. R. (2001) Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions. Ann. Allergy Asthma Immunol. 87: 201-204
240. Sandrini, M., Vitale, G., Pini, L. A. (2002) Effect of rofecoxib on nociception and the serotonin system in the rat brain. Inflamm. Res. 51: 154-159
241. Scheen, A. J. (2000) Pharma-clinics. The drug of the month. Rofecoxib (Vioxx). Rev. Med. Liege. 55: 751-753
242. Scheiman, J. M. (2002) Outcomes studies of the gastrointestinal safety of cyclooxygenase-2 inhibitors. Cleve. Clin. J. Med. 69 (Suppl. 1): SI40-SI46
243. Schnitzer, T. J. (2001) Osteoarthritis management: The role of cyclooxygenase-2-selective inhibitors. Clin. Ther. 23: 313-326
244. Schnitzer, T. J., Hochberg, M. C. (2002) COX-2-selective inhibitors in the treatment of arthritis. Cleve. Clin. J. Med. 69 (Suppl. 1): SI20-SI30
245. Schnitzer, T. J., Truitt, K., Fleischmann, R., Dalgin, P., Block, J., Zeng, Q., Bolognese, J., Seidenberg, B., Ehrich, E. W. (1999) The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II rofecoxib rheumatoid arthritis study group. Clin. Ther. 21: 1688-1702
246. Schoors, D. (2002) A comparison of the renal and cardiovascular safety of celecoxib and rofecoxib. Clin. Ther. 24: 468-469
247. Schwartz, J., Hsieh, P., Ebel, D., Hunt, T., Gertz, B. (1997) Influence of selective cyclooxygenase-2 inhibitor, MK-0966, on ethinylestradiol (EE) and norethindrone (NET) serum concentrations. Eur. J. Clin. Pharmacol. 52 (Suppl.): A113
248. Schwartz, J. I., Chan, C. C., Mukhopadhyay, S., McBride, K. J., Jones, T. M., Adcock, S., Moritz, C., Hedges, J., Grasing, K., Dobratz, D., Cohen, R. A., Davidson, M. H., Bachmann, K. A., Gertz, B. J. (1999) Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans. Clin. Pharmacol. Ther. 65: 653-660
249. Schwartz, J., Zhao, P., Gertz, B., Gumbs, C., Ebel, D., Lasseter, K., Porras, A. (2000a) Pharmacokinetics of rofecoxib in mild to moderate hepatic insufficiency (HI). (abstract) Clin. Pharmacol. Ther. 67: 137, PII-90
250. Schwartz, J. I., Bugianesi, K. J., Ebel, D. L., De Smet, M., Haesen, R., Larson, P. J., Ko, A., Verbesselt, R., Hunt, T. L., Lins, R., Lens, S., Porras, A. G., Dieck, J., Keymeulen, B, Gertz, B. J. (2000b) The effect of rofecoxib on the pharmacodynamics and pharmacokinetics of warfarin. Clin. Pharmacol. Ther. 68: 626-636
251. Schwartz, J. I., Agrawal, N. G., Wong, P. H., Bachmann, K. A., Porras, A. G., Miller, J. L., Ebel, D. L., Sack, M. R., Holmes, G. B., Redfern, J. S., Gertz, B. J. (2001a) Lack of pharmacokinetic interaction between rofecoxib and methotrexate in rheumatoid arthritis patients. J. Clin. Pharmacol. 41: 1120-1130
252. Schwartz, J. I., De Smet, M., Larson, P. J., Verbesselt, R., Ebel, D. L., Lins, R., Lens, S., Porras, A. G., Gertz, B. J. (2001b) Effect of rofecoxib on the pharmacokinetics of digoxin in healthy volunteers. J. Clin. Pharmacol. 41: 107-112
253. Schwartz, J. I., Wong, P. H., Porras, A. G., Ebel, D. L., Hunt, T. R., Gertz, B. J. (2002) Effect of rofecoxib on the pharmacokinetics of chronically administered oral contraceptives in healthy female volunteers. J. Clin. Pharmacol. 42: 215-221
254. Schwartz, J. I., Mukhopadhyay, S., Porras, A. G., Viswanathan-Aiyer, K. J., Adcock, S., Ebel, D. L., Gertz, B. J. (2003) Effect of rofecoxib on prednisolone and prednisone pharmacokinetics in healthy subjects. J. Clin. Pharmacol. 43: 187-192
255. Scott, L. J., Lamb, H. M. (1999) Rofecoxib. Drugs 58: 499-505
256. Searle & Co., Inc. (1999) US FDA draft label for Celebrex (Celecoxib capsules). Available at www.fda.gov/cder/foi/label/1998/209981bl.pdf (accessed 10 April 2003)
257. Searle Ltd (2002) Information on clinical pharmacology of Valdecoxib. Available at www.rxlist.com/cgi/generic/bextra_cp.htm (accessed 12 April 2003)
258. Seibold, J. R., Spector, R. (2001) NSAIDs and COX-2 inhibitors: Selective vs standard use. Med. Crossfire 3: 49-53
259. Selzer, T. (2002) Dermal Therapeutic System Containing Non-Steroidal Antiphlogistics with Selective COX-2 Inhibition. LTS Lohmann Therapie-Systeme Ag, Germany DE 10032132
260. Shen, F., Bai, A. P., Guo, Z. R., Cheng, G. F. (2002) Inhibitory effect of 3,4-diaryl-3-pyrrolin-2-one derivatives on cyclooxygenase 1 and 2 in murine peritoneal macrophages. Acta. Pharmacol. Sin. 23: 762-768
261. Sigthorsson, G., Crane, R., Simon, T., Hoover, M., Quan, H., Bolognese, J. A., Bjarnason, I. (2000) COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: A double blind crossover study comparing rofecoxib with placebo and indomethacin. Gut 47: 527-532
262. Simitchieva, K., Reines, S. A., McKinney, E., Sandquiest, E. J., Khannna, D. K., Hargreaves, R. (2002) Method of Treating Migraines and Pharmaceutical Compositions. Merck & Co., Inc., Rahway, NJ. US 6384034
263. Simon, L. S. (2001) COX-2 inhibitors. Are they nonsteroidal antiinflammatory drugs with a better safety profile? Gastroenterol. Clin. North Am. 30: 1011-1025
264. Sinatra, R. (2002) Role of cox-2 inhibitors in the evolution of acute pain management. J. Pain Symptom Manage. 24(Suppl. 1):S18
265. Singh, A., Jain, R. (2001) Antiinflammatory and Analgesic Composition Containing COX-2 Inhibitors for Topical and Transdermal Uses. Panacea Biotec Ltd, India. WO 2001052897
266. Singh, B., Singh, A., Ahuja, N. (2003) Studies on dissolution enhancement of rofecoxib using water-soluble carriers. In: National Seminar on Pharmaceutics in the Light of Drug Delivery Challenges. Chandigarh, India, 14-15 March (abstract) P-11
267. Singh, G., Ramey, D. R., Morfield, D., Shi, H., Hatoum, H. T., Fries, J. F. (1996) Gastrointestinal tract complications of nonsteroidal antiinflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch. Intern. Med. 156: 1530-1536
268. Singla, A. K., Chawla, M., Singh, A. (2000) Nimesulide: Some pharmaceutical and pharmacological aspects - An update. J. Pharm. Pharmacol. 52: 467-486
269. Slaughter, R. L., Edwards, D. J. (1995) Recent advances: The cytochrome P450 enzymes. Ann. Pharmacother. 29: 69-624
270. Smith, W. L., DeWitt, D. L. (1996) Prostaglandin endoperoxide H synthases-1 and -2. Adv. Immunol. 62: 167-215
271. Smith, W. L., Garovito, D. E., DeWitt, D. L. (1996) Prostaglandin endoperoxide H synthases (cyclooxygenase)-1 and -2. J. Biol. Chem. 271: 33157-33160
272. Steinfeld, S., Poriau, S. (2001) Patient and physician satisfaction with rofecoxib in osteoarthritis: Results of the EVA (experience with VIOXX in arthritis) survey. Curr. Med. Res. Opin. 17: 81-87
273. Steinfeld, S., Bjorke, P. A. (2002) Results from a patient survey to assess gastrointestinal burden of non-steroidal anti-inflammatory drug therapy contrasted with a review of data from EVA to determine satisfaction with rofecoxib. Rheumatology 41 (Suppl. 1): 23-27
274. Stevenson, D. D., Simon, R. A. (2001) Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma. J. Allergy Clin. Immunol. 108: 47-51
275. Straub, J., Bernstein, H., Chickering, III, Donald, E., Khattak, S., Randall, G. (2002) Porous Drug Matrices and Methods of Manufacture Thereof. Acusphere, Inc., Cambridge, MA. USA 6395300
276. Sundy, J. S. (2001) COX-2 inhibitors in rheumatoid arthritis. Curr. Rheumatol. Rep. 3: 86-91
277. Supersaxo, A. W., Weder, M. A., Weder, H. G. (2002) Microemulsion preconcentrates as pharmaceutical formulations for anti-inflammatory compounds with low solubility. Vesifact Ag, Switzerland. Eur. Pat. Appl., EP 1249231
278. Swan, S. K., Rudy, D. W., Lasseter, K. C., Ryan, C. F., Buechel, K. L., Lambrecht, L. J., Pinto, M. B., Dilzer, S. C., Obrda, O., Sundblad, K. J., Gumbs, C. P., Ebel, D. L., Quan, H., Larson, P. J., Schwartz, J. I., Musliner, T. A., Gertz, B. J., Brater, D. C., Yao, S. L. (2000) Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. Ann. Intern. Med. 133: 1-9
279. Szczeklik, A., Nizankowska, E., Bochenek, G., Nagraba, K., Mejza, F., Swierczynska, M. (2001) Safety of a specific COX-2 inhibitor in aspirin-induced asthma. Clin. Exp. Allergy 31: 219-225
280. Tanaka, A., Araki, H., Komoike, Y., Hase, S., Takeuchi, K. (2001) Inhibition of both COX-1 and COX-2 is required for development of gastric damage in response to nonsteroidal antiinflammatory drugs. J. Physiol. Paris 95: 21-27
281. Tanaka, A., Araki, H., Hase, S., Komoike, Y., Takeuchi, K. (2002a) Up-regulation of COX-2 by inhibition of COX-1 in the rat: A key to NSAID-induced gastric injury. Aliment. Pharmacol. Ther. 16 (Suppl. 2): 90-101
282. Tanaka, A., Hase, S., Miyazawa, T., Takeuchi, K. (2002b) Up-regulation of cyclooxygenase-2 by inhibition of cyclooxygenase-1: A key to nonsteroidal antiinflammatory drug-induced intestinal damage. J. Pharmacol. Exp. Ther. 300: 754-761
283. Thérien, M., Gauthier, J. Y., Leblanc, Y., Léger, S., Perrier, H., Prasit, P., Wang, Z. (2001) Synthesis of rofecoxib, (MK 0966, Vioxx 4-(4′-methylsulphonylphenyl)-3-phenyl-2(5H)-furanone), a selective and orally active inhibitor of cyclooxygenase-2. Synthesis 12: 1778-1779
284. Truitt, K. E., Sperling, R. S., Ettinger, W. H., Greenwald, M., DeTora, L., Zeng, Q. Bolognese, J., Ehrich, E. (2001) A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis. Aging (Milano) 13: 112-121
285. Vadas, P., Stefanski, E., Wloch, M., Grouix, B., Van Den Bosch, H., Kennedy, B. (1996) Secretory non-pancreatic phospholipase A2 and cyclooxygenase-2 expression by tracheobronchial smooth muscle cells. Eur. J. Biochem. 235: 557-563
286. Van Hecken, A., Schwartz, J. I., Depre, M., De Lepeleire, I., Dallob, A., Tanaka, W., Wynants, K., Buntinx, A., Arnout, J. , Wong, P. H., Ebel, D. L., Gertz, B. J., De Schepper, P. J. (2000) Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J. Clin. Pharmacol. 40: 1109-1120
287. Vane, J. R. (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. 231: 232-235
288. Vane, J. R., Botting, R. M. (1995) New insights into the mode of action of antiinflammatory drugs. Inflamm. Res. 44: 1-10
289. Verma, S., Raj, S. R., Shewchuk, L., Mather, K. J., Anderson, T. J. (2001) Cyclooxygenase-2 blockade does not impair endothelial vasodilator function in healthy volunteers: Randomized evaluation of rofecoxib versus naproxen on endothelium-dependent vasodilatation. Circulation 104: 2879-2882
290. Wahba, A. L., Soper, C. (2001) Acute, anuric renal failure associated with two doses of a cyclooxygenase-2 inhibitor. Nephron 89: 239
291. Watson, D. J., Harper, S. E., Zhao, P. L., Quan, H., Bolognese, J. A., Simon, T. J. (2000) Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch. Intern. Med. 160: 2998-3003
292. Watson, D. J., Harper, S. E., Zhao, P. L., Bolognese, J. A., Simon, T. J. (2001) Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs. Med. Gen. Med. 3: 6
293. Weaver, A. L. (2001) Rofecoxib: Clinical pharmacology and clinical experience. Clin. Ther. 23: 1323-1338
294. Weaver, J., Bonnel, R. A., Karwoski, C. B., Brinker, A. D., Beitz, J. (2001) GI events leading to death in association with celecoxib and rofecoxib. Am. J. Gastroenterol. 96: 3449-3450
295. Werner, U., Werner, D., Mundkowski, R., Gillich, M., Brune, K. (2001) Selective and rapid liquid chromatography-mass spectrometry method for the quantification of rofecoxib in pharmacokinetic studies with humans. J. Chromatogr. B Biomed. Sci. Appl. 760: 83-90
296. Whelton, A. (2001) Cyclooxygenase-2 inhibition and renal function. Ann. Intern. Med. 134: 1077-1078
297. Whelton, A., Fort, J. G., Puma, J. A., Normandin, D., Bello, A. E., Verburg, K. M. (2001) Cyclooxygenase-2-specific inhibitors and cardiorenal function: A randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am. J. Ther. 8: 85-95
298. Wight, N. J., Gottesdiener, K., Garlick, N. M., Atherton, C. T., Novak, S., Gertz, B. J., Calder, N. A., Cote, J., Wong, P., Dallob, A., Hawkey, C. J. (2001) Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production. Gastroenterology 120: 867-873
299. Wilson, K. T., Fu, S., Ramanujam, K. S., Meltzer, S. J. (1998) Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's oesophagus and associated adenocarcinomas. Cancer Res. 58: 2929-2934
300. Wockhardt (2002) Wockhardt second quarter 2002 financial results. www.wockhardtin.com/pr_31ajuly2002.htm (accessed 14 April 2003)
301. Wolf, G., Porth, J., Stahl, R. A. (2000) Acute renal failure associated with rofecoxib. Ann. Intern. Med. 133: 394
302. Wolfe, F., Anderson, J., Burke, T. A., Arguelles, L. M., Pettitt, D. (2002) Gastroprotective therapy and risk of gastrointestinal ulcers: Risk reduction by COX-2 therapy. J. Rheumatol. 29: 467-473
303. Wong, E., DeLuca, C., Boily, C., Charleson, S., Cromlish, W., Denis, D., Kargman, S., Kennedy, B. P., Ouellet, M., Skorey, K., O'Neill, G. P., Vickers, P. J., Riendeau, D. (1997) Characterization of autocrine inducible prostaglandin H synthase-2 (PGHS-2) in human osteosarcoma cells. Inflamm. Res 46: 51-59
304. Woolf, E., Fu, I., Matuszewski, B. (1999) Determination of rofecoxib, a cyclooxygenase-2 specific inhibitor, in human plasma using high-performance liquid chromatography with post-column photochemical derivatization and fluorescence detection. J. Chromatogr. B. Biomed. Sci. Appl. 730: 221-227
305. Woywodt, A., Schwarz, A., Mengel, M., Haller, H., Zeidler, H., Kohler, L. (2001) Nephrotoxicity of selective COX-2 inhibitors. J. Rheumatol. 28: 2133-2135
306. Wu, A., Wang, Q., Wang, Q., Xu, H., Cheng, M., (2002) Synthesis of new cyclooxygenase-2 inhibitor: Rofecoxib. Zhongguo Yaowu Huaxue Zazhi 12: 37-38
307. Zacher, J., Schattenkirchner, M. (2002) Patient and physician satisfaction with rofecoxib in osteoarthritis: Results of a post-marketing surveillance study in primary care in Germany. Curr. Med. Res. Opin. 18: 229-236
308. Zhao, S. Z., Reynolds, M. W., Lejkowith, J., Whelton, A., Arellano, F. M. (2001) A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database. Clin. Ther. 23: 1478-1491
309. Ziegler, J. (1999) Early trials probe COX-2 inhibitors' cancer-fighting potential. J. Natl Cancer Inst. 91: 1186-1187